Last reviewed · How we verify
Nasal Dexamethasone
At a glance
| Generic name | Nasal Dexamethasone |
|---|---|
| Also known as | Nasal DXM |
| Sponsor | Edda Sciutto Conde |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Effects of Red and Infrared Photobiomodulation in Rhinoplasty at a Single Centre (NA)
- Soaked Pharyngeal Packing Agents in Septoplasty (PHASE3)
- PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma (NA)
- Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma (PHASE2)
- Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma (EARLY_PHASE1)
- Anesthetic Optimization in Pediatric LeFort Surgeries (NA)
- Trans-nasal Sphenopalatine Ganglion Block Versus Ultrasound-guided Bilateral Greater and Lesser Occipital Nerve Block for Management of Post-Dural Puncture Headache. (NA)
- Safety and Efficacy of DSM 32444 Postbiotic in the Treatment of Acute Rhinosinusitis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nasal Dexamethasone CI brief — competitive landscape report
- Nasal Dexamethasone updates RSS · CI watch RSS
- Edda Sciutto Conde portfolio CI